How large is the desmoplastic small round cell tumor treatment market, and what is its growth trajectory?
The desmoplastic small round cell tumor treatment market size has grown strongly in recent years. It will grow from $3.7 billion in 2024 to $4.02 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rise in awareness of rare cancers, rise in number of clinical trials, growth in funding for rare cancer research, increase in availability of advanced diagnostics, and growth in immunotherapies and gene therapies.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to growing specialized treatment centers, growing personalized medicine, rising use of combination therapies, growing new drug approvals, and rising healthcare expenditure on cancer treatment. Major trends in the forecast period include adoption of targeted therapies, integration of advanced diagnostics, implementation of personalized medicine, advancements in gene editing technologies, and development of enhanced drug delivery systems.
Get Your Free Sample of The Global Desmoplastic Small Round Cell Tumor Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19029&type=smp
What are the key forces behind the desmoplastic small round cell tumor treatment market’s growth in recent years?
The increased focus on personalized medicine is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Personalized medicine involves customizing healthcare based on a patient’s unique genetic profile, lifestyle, and environment. It includes approaches such as pharmacogenomics, targeted therapies, and gene editing to provide more precise and effective treatments. The growing emphasis on personalized medicine is driven by advancements in genomics, improved patient outcomes, and the potential for more targeted and effective treatments. Personalized medicine helps in treating desmoplastic small round cell tumor (DSRCT) by tailoring therapies based on the tumor’s specific genetic and molecular profile, enabling targeted treatments that improve efficacy and reduce side effects. For instance, according to Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the approval of 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, increased focus on personalized medicine is driving the desmoplastic small round cell tumor treatment market.
What are the major segments of the desmoplastic small round cell tumor treatment market?
The desmoplastic small round cell tumor treatmentmarket covered in this report is segmented –
1) By Type: Immunotherapy, Surgical Operation, Chemotherapy, Radiotherapy
2) By Drug Class: Cytotoxic Agents, Targeted Therapies, Immunomodulators
3) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Monoclonal Antibodies, Immune Modulators
2) By Surgical Operation: Tumor Resection, Debulking Surgery, Laparoscopic Surgery
3) By Chemotherapy: Neoadjuvant Chemotherapy, Adjuvant Chemotherapy, Targeted Therapy Agents
4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Stereotactic Radiosurgery (SRS)
Order your report now for swift delivery
Which companies dominate the desmoplastic small round cell tumor treatment market?
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc
What are the key regional dynamics of the desmoplastic small round cell tumor treatment market, and which region leads in market share?
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2024. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Desmoplastic Small Round Cell Tumor Treatment Market Report 2025 Offer?
The desmoplastic small round cell tumor treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Desmoplastic small round cell tumor treatment encompasses various medical approaches, such as surgery, chemotherapy, and radiation therapy, designed to manage and control the progression of DSRCT, a rare and aggressive form of cancer. These treatments are used to target and limit the spread of cancerous cells, primarily in the abdominal area. The key benefit of DSRCT treatment is its potential to reduce tumor size, improve survival rates, and enhance the patient’s overall quality of life.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19029
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
